Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Onco Therapeutics
Onco Therapeutics is not currently indexed in Scopus. Published by Begell House Inc..
Checked against the index lists dated .
ISSN 2694-4642Verify ISSN ↗2694-4650Verify ISSN ↗
Publisher: Begell House Inc.
Cost to publish: No APC data — check the publisher
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is Onco Therapeutics indexed in Scopus?
No — it was previously covered by Scopus but its coverage is now inactive/discontinued (2021–2022).
What is the impact factor of Onco Therapeutics?
Onco Therapeutics has no Journal Impact Factor — JIF is published only for journals in the Web of Science Core Collection (SCIE, SSCI, AHCI and ESCI) — and Scopus has not published a current CiteScore for it either. Treat any "impact factor" quoted for this journal elsewhere as unofficial. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.309, quartile Q3, with an H-index of 3.
Who publishes Onco Therapeutics and what is its ISSN?
Onco Therapeutics is published by Begell House Inc. Its print ISSN is 2694-4642 and its online ISSN is 2694-4650.
Is Onco Therapeutics in Web of Science?
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
Is Onco Therapeutics open access?
No — it is not registered as an open-access journal in DOAJ or Scopus.
Scopus coverage history
Scopus indexed Onco Therapeutics for 2 years, between 2021 and 2022. Coverage ended in 2022, 4 years ago, and Scopus now lists the title as inactive.
Is it still publishing? OpenAlex lists 30 works and 51 citations for the title. Its most recent paper is from 2022, in line with the end of Scopus coverage in 2022, which suggests the journal stopped publishing around then.
How well cited is Onco Therapeutics? — open metrics via OpenAlex
Onco Therapeutics has an h-index of 4 and a 2-year mean of 0 citations per paper (OpenAlex).
Onco Therapeutics published 17 papers in 2022. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. Updated 2026-10-14.
Who publishes in Onco Therapeutics? — latest 22 articles, 2021–2022
In its latest 22 research articles (2021–2022), authors are most often from India (31.8%), United States (29.5%) and Italy (11.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for Onco Therapeutics? — indicators, not proof of misconduct
Scopus status: Inactive — coverage ended 2022. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusInactive — coverage ended 2022
- Retracted papers None recorded
- Problematic Paper Screener flags None flagged
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
More from Begell House Inc.
Begell House Inc. has 41 other titles in our data; 33 are currently indexed in Scopus.
Related journals
8 journalsIndex data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.